How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?

The NADINA trial (NCT04949113) has clearly established that the neoadjuvant approach affords a better EFS in patients with clinical stage III melanoma. However, there is no direct comparison between anti-PD1 monotherapy and dual checkpoint inhibition in the neoadjuvant setting. I do not think that s...